Treatment of HNF1A-MODY with SGLT2 inhibition

Keyphrases

• Sodium-glucose Cotransporter 100%
• HNF1A-MODY 100%
• Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i) 50%
• Urinary Glucose Excretion 25%
• Glucose-lowering Drugs 25%
• HNF1A 25%
• Empagliflozin 25%
• Monogenic Diabetes 25%
• Diabetes 16%
• Type 2 Diabetes Prevention 16%
• Glycaemia 16%
• Disease Variants 16%
• No Significant Difference 8%
• Placebo 8%
• Placebo-controlled 8%
• Drug Use 8%
• Randomized Trial 8%
• Glucose Transport 8%
• Type 2 Diabetes Mellitus (T2DM) 8%
• Insulin 8%
• β-cell Function 8%
• Randomized Double-blind 8%
• Clinical Application 8%
• Drug Class 8%
• Glucose-insulin System 8%
• Transcription Factor 8%
• Early Onset 8%
• Continuous Glucose Monitoring 8%
• Hyperglycemic Clamp 8%
• Impaired Insulin Secretion 8%
• Non-insulin 8%
• Safety Issues 8%
• Glucosuria 8%
• Distinct Subtypes 8%
• Large Degree 8%
• Renal Glucose Reabsorption 8%
• Glucose Threshold 8%
• Patients with Diabetes 8%
• Well Tolerated 8%
• Mean Blood Glucose 8%
• Distinct Phenotype 8%
• Renal Threshold for Glucose 8%

Biochemistry, Genetics and Molecular Biology

• Cotransporter 100%
• HNF1A 100%
• Glucose 100%
• Maturity Onset Diabetes of the Young 100%
• Sodium-Glucose Cotransporter 2 Inhibitors 40%
• Glucose Urine Level 20%
• Glucose Blood Level 13%
• Insulin 13%
• Glucose Transport 6%
• Cell Function 6%
• Insulin Release 6%
• Transcription Factors 6%